ADVERTISEMENT
GSK Pharma Q4 Review: ICICI Securities Downgrades To 'Reduce' On Expensive Valuation, But Hikes Target Price
ICICI Securities downgrade GSK Pharma to Reduce on expensive valuation; raises target price to Rs 2,600 based on 38x FY27E EPS.
14 May 2025, 10:37 AM IST 
GSK Pharma's Ebitda margin touches a new high of 34% in Q4 FY25 (Photo Source: freepik)
GSK Pharma's revenue for the recently launched patented brands Nucala and Trelegy was Rs 1.0 billion–1.5 billion in FY25. Respiratory portfolio led by Nucala and Trelegy continues to gain market share, while monthly doses of Shingrix surged to a high of 10,000 in Mar’25.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
